Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab

Fingolimod is used for the treatment of multiple sclerosis (MS) and targets receptors for the bioactive sphingolipid sphingosine-1-phosphate. Whether fingolimod or other MS therapies conversely affect plasma concentrations of sphingolipids has, however, not yet been analyzed. Herein, we quantified 1...

Descripción completa

Detalles Bibliográficos

Autores principales:	Florian Ottenlinger, Christoph Alexander Mayer, Nerea Ferreirós, Yannick Schreiber, Anja Schwiebs, Katrin Schmidt, Hanns Ackermann, Josef Pfeilschifter, Heinfried H. Radeke
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2016-11-01
Colección:	Frontiers in Pharmacology
Materias:	Ceramides Interferon-beta Multiple Sclerosis Sphingolipids fingolimod natalizumab
Acceso en línea:	http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00412/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!